Physician profile
Alan Green
NPI 1609907732
$497.83
in general payments reported to CMS, 2019-2025
12 companies · $15.18 in 2025
The $15.18 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $98.16 · 2021: $104 · 2022: $70.69 · 2023: $49.63 · 2025: $15.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $64.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $64.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $156.95 | 2019-2022 | |
| Glaxosmithkline, LLC. | $143.70 | 2020-2025 | Trelegy Ellipta, Nucala |
| Genzyme Corporation | $38.82 | 2019-2023 | |
| Amgen INC. | $26.65 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.33 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $20.04 | 2021 | |
| Merck Sharp & Dohme LLC | $17.42 | 2019 | |
| Mylan Specialty L.P. | $17.20 | 2023 | Yupelri |
| Optinose US, INC. | $16.59 | 2019 | |
| Boston Scientific Corporation | $13.27 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.56 | 2021 | |
| Circassia INC. | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.